China Pharma Holdings, Inc. (CPHI)
USD 0.17
(-9.78%)
USD 0.17
(-9.78%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.75 Million USD | 22.46% |
| 2022 | -3.54 Million USD | -13.91% |
| 2021 | -3.11 Million USD | -26.79% |
| 2020 | -2.45 Million USD | 27.5% |
| 2019 | -3.38 Million USD | 14.58% |
| 2018 | -3.96 Million USD | 11.74% |
| 2017 | -4.49 Million USD | -7.22% |
| 2016 | -4.19 Million USD | 70.46% |
| 2015 | -14.19 Million USD | 61.16% |
| 2014 | -36.54 Million USD | -145.17% |
| 2013 | -14.9 Million USD | -329.4% |
| 2012 | 6.49 Million USD | -70.5% |
| 2011 | 22.02 Million USD | -10.7% |
| 2010 | 24.66 Million USD | 9.07% |
| 2009 | 22.61 Million USD | 14.62% |
| 2008 | 19.73 Million USD | 61.05% |
| 2007 | 12.25 Million USD | 42.07% |
| 2006 | 8.62 Million USD | 103.2% |
| 2005 | 4.24 Million USD | 3715.79% |
| 2004 | -117.36 Thousand USD | 24.59% |
| 2003 | -155.64 Thousand USD | 78.23% |
| 2002 | -714.83 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -916.05 Thousand USD | 22.66% |
| 2024 Q2 | -1.39 Million USD | -51.9% |
| 2023 Q2 | -456.3 Thousand USD | -147.87% |
| 2023 FY | -2.75 Million USD | 22.46% |
| 2023 Q1 | 953.19 Thousand USD | 180.84% |
| 2023 Q3 | -713.54 Thousand USD | -56.37% |
| 2023 Q4 | -1.18 Million USD | -66.0% |
| 2022 Q2 | -779.59 Thousand USD | 14.49% |
| 2022 Q3 | -688.65 Thousand USD | 11.66% |
| 2022 FY | -3.54 Million USD | -13.91% |
| 2022 Q1 | -911.71 Thousand USD | -217.98% |
| 2022 Q4 | -1.17 Million USD | -71.23% |
| 2021 FY | -3.11 Million USD | -26.79% |
| 2021 Q1 | -696.46 Thousand USD | 36.77% |
| 2021 Q2 | -752.94 Thousand USD | -8.11% |
| 2021 Q3 | -762.4 Thousand USD | -1.26% |
| 2021 Q4 | 772.74 Thousand USD | 201.36% |
| 2020 Q1 | -599.28 Thousand USD | 63.91% |
| 2020 FY | -2.45 Million USD | 27.5% |
| 2020 Q3 | -952.49 Thousand USD | -1370.25% |
| 2020 Q2 | 74.98 Thousand USD | 112.51% |
| 2020 Q4 | -1.1 Million USD | -15.64% |
| 2019 Q1 | -334.2 Thousand USD | 67.61% |
| 2019 FY | -3.38 Million USD | 14.58% |
| 2019 Q3 | -645.2 Thousand USD | 14.31% |
| 2019 Q2 | -752.96 Thousand USD | -125.3% |
| 2019 Q4 | -1.66 Million USD | -157.34% |
| 2018 FY | -3.96 Million USD | 11.74% |
| 2018 Q4 | -1.03 Million USD | 46.58% |
| 2018 Q3 | -1.93 Million USD | -123.44% |
| 2018 Q2 | -864.4 Thousand USD | -514.42% |
| 2018 Q1 | -140.68 Thousand USD | 91.57% |
| 2017 Q2 | -1.15 Million USD | -43.71% |
| 2017 Q3 | -871.25 Thousand USD | 24.47% |
| 2017 Q4 | -1.66 Million USD | -91.53% |
| 2017 FY | -4.49 Million USD | -7.22% |
| 2017 Q1 | -802.63 Thousand USD | -40.87% |
| 2016 Q4 | -569.78 Thousand USD | 36.91% |
| 2016 FY | -4.19 Million USD | 70.46% |
| 2016 Q1 | -1.32 Million USD | 77.67% |
| 2016 Q2 | -1.39 Million USD | -5.88% |
| 2016 Q3 | -903.1 Thousand USD | 35.45% |
| 2015 Q4 | -5.91 Million USD | -285.29% |
| 2015 Q2 | -3.8 Million USD | 50.39% |
| 2015 Q1 | -7.66 Million USD | 65.09% |
| 2015 FY | -14.19 Million USD | 61.16% |
| 2015 Q3 | 3.19 Million USD | 183.96% |
| 2014 Q1 | -2.33 Million USD | 47.58% |
| 2014 Q2 | -8.52 Million USD | -264.96% |
| 2014 Q3 | -3.71 Million USD | 56.42% |
| 2014 Q4 | -21.96 Million USD | -491.04% |
| 2014 FY | -36.54 Million USD | -145.17% |
| 2013 Q1 | -3 Million USD | -303.25% |
| 2013 Q2 | -4.76 Million USD | -58.67% |
| 2013 Q3 | -2.68 Million USD | 43.55% |
| 2013 Q4 | -4.45 Million USD | -65.86% |
| 2013 FY | -14.9 Million USD | -329.4% |
| 2012 Q4 | -744.06 Thousand USD | -145.99% |
| 2012 FY | 6.49 Million USD | -70.5% |
| 2012 Q3 | 1.61 Million USD | -26.81% |
| 2012 Q2 | 2.21 Million USD | -35.25% |
| 2012 Q1 | 3.41 Million USD | -51.43% |
| 2011 FY | 22.02 Million USD | -10.7% |
| 2011 Q4 | 7.02 Million USD | 80.33% |
| 2011 Q3 | 3.89 Million USD | -32.33% |
| 2011 Q2 | 5.75 Million USD | 7.89% |
| 2011 Q1 | 5.33 Million USD | -30.54% |
| 2010 Q4 | 7.68 Million USD | 24.05% |
| 2010 Q3 | 6.19 Million USD | 12.85% |
| 2010 FY | 24.66 Million USD | 9.07% |
| 2010 Q2 | 5.49 Million USD | 13.72% |
| 2010 Q1 | 4.82 Million USD | -15.27% |
| 2009 Q2 | 4.8 Million USD | 18.19% |
| 2009 FY | 22.61 Million USD | 14.62% |
| 2009 Q4 | 5.69 Million USD | -29.23% |
| 2009 Q3 | 8.05 Million USD | 67.66% |
| 2009 Q1 | 4.06 Million USD | -32.13% |
| 2008 Q2 | 4.39 Million USD | -5.55% |
| 2008 Q4 | 5.98 Million USD | 27.53% |
| 2008 FY | 19.73 Million USD | 61.05% |
| 2008 Q3 | 4.69 Million USD | 6.8% |
| 2008 Q1 | 4.65 Million USD | -3.6% |
| 2007 FY | 12.25 Million USD | 42.07% |
| 2007 Q4 | 4.82 Million USD | 54.55% |
| 2007 Q1 | 934.55 Thousand USD | -65.35% |
| 2007 Q2 | 3.36 Million USD | 260.12% |
| 2007 Q3 | 3.12 Million USD | -7.19% |
| 2006 Q2 | 1.35 Million USD | -27.1% |
| 2006 Q1 | 1.85 Million USD | 0.0% |
| 2006 Q3 | 2.07 Million USD | 53.32% |
| 2006 Q4 | 2.69 Million USD | 30.11% |
| 2006 FY | 8.62 Million USD | 103.2% |
| 2005 Q2 | -1.77 Million USD | -4260.15% |
| 2005 FY | 4.24 Million USD | 3715.79% |
| 2005 Q1 | -40.67 Thousand USD | -134.36% |
| 2005 Q3 | 687.5 Thousand USD | 138.76% |
| 2004 Q3 | -10.72 Thousand USD | 70.2% |
| 2004 Q4 | -17.35 Thousand USD | -61.85% |
| 2004 FY | -117.36 Thousand USD | 24.59% |
| 2004 Q2 | -35.98 Thousand USD | -1127.44% |
| 2004 Q1 | 3502.00 USD | 722.02% |
| 2003 Q4 | -563.00 USD | 99.35% |
| 2003 Q2 | -46.55 Thousand USD | 21.7% |
| 2003 Q1 | -59.45 Thousand USD | 25.43% |
| 2003 Q3 | -86.82 Thousand USD | -86.51% |
| 2003 FY | -155.64 Thousand USD | 78.23% |
| 2002 FY | -714.83 Thousand USD | 0.0% |
| 2002 Q4 | -79.73 Thousand USD | -256.42% |
| 2002 Q3 | 50.97 Thousand USD | 142.33% |
| 2002 Q2 | -120.4 Thousand USD | 65.25% |
| 2002 Q1 | -346.54 Thousand USD | -295.16% |
| 2001 Q4 | -87.69 Thousand USD | 45.25% |
| 2001 Q3 | -160.17 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| cbdMD, Inc. | -9.26 Million USD | 70.31% |
| cbdMD, Inc. | -9.26 Million USD | 70.31% |
| Zomedica Corp. | -31.59 Million USD | 91.29% |